WS
BIOL

Wedbush Securities’s Biolase, Inc. BIOL Stock Holding History

Wedbush Securities’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed -$4K – 913
2018
Q1 		$4K Hold
1
– – ﹤0.01% 815
2017
Q4 		$4K Hold
1
– – ﹤0.01% 852
2017
Q3 		$6K Hold
1
– – ﹤0.01% 832
2017
Q2 		$10K Hold
1
– – ﹤0.01% 832
2017
Q1 		$14K Hold
1
– – ﹤0.01% 829
2016
Q4 		$14K Hold
1
– – ﹤0.01% 809
2016
Q3 		$18K Hold
1
– – ﹤0.01% 817
2016
Q2 		$12K Hold
1
– – ﹤0.01% 777
2016
Q1 		$14K Hold
1
– – ﹤0.01% 739
2015
Q4 		$9K Hold
1
– – ﹤0.01% 732
2015
Q3 		$9K Buy
+1
New +$18.6K ﹤0.01% 712

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCM
Princeton Capital Management Red Bank, New Jersey $367M AUM 45.24% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

Wedbush Securities's BIOL Position: Q2 2018 in Review

Wedbush Securities sold out of Biolase, Inc. (BIOL) in Q2 2018, closing a stake of 1 share — an estimated $4K sold.

Wedbush Securities first reported a position in BIOL in Q3 2015 and held it in 11 quarters. The position peaked at $18K in Q3 2016. 18 funds tracked by Wall St. Rank hold BIOL as of Q2 2018.

  • Wedbush Securities reported no remaining Biolase, Inc. position as of Q2 2018 after selling out during the quarter.
  • Wedbush Securities sold 1 Biolase, Inc. share in Q2 2018, an estimated $4K.
  • Wedbush Securities first reported a position in Biolase, Inc. in Q3 2015 and held it in 11 quarters.
  • Wedbush Securities's Biolase, Inc. position peaked at $18K in Q3 2016.
  • 18 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2018.

Based on Wedbush Securities's 13F filing for Q2 2018, filed 3 Aug 2018.